Trial Profile

A PHASE 2, OPEN-LABEL TRIAL OF DACOMITINIB (PF-00299804) IN SELECTED PATIENTS WITH ADVANCED ADENOCARCINOMA OF THE LUNG

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dacomitinib (Primary)
Indications Adenocarcinoma; Lung cancer; Non-small cell lung cancer
Focus Therapeutic Use
Sponsors Pfizer

Most Recent Events

31 Jan 2021 Data (n=266) pooled from two studies (Study 1017 and ARCHER 1050) were used for longitudinal tumor growth inhibition model to evaluate the effectiveness of the dacomitinib dosing regimen methods, presented at the 2020 World Conference on Lung Cancer.
12 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
19 May 2015 Planned End Date changed from 1 Mar 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com